Edition:
United States

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

2.78USD
28 Apr 2017
Change (% chg)

$0.18 (+6.92%)
Prev Close
$2.60
Open
$2.60
Day's High
$2.80
Day's Low
$2.59
Volume
51,315
Avg. Vol
50,638
52-wk High
$5.51
52-wk Low
$1.74

Latest Key Developments (Source: Significant Developments)

Scynexis delays initiation of new clinical studies
Thursday, 2 Mar 2017 04:05pm EST 

Scynexis Inc : Scynexis delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA's request . Scynexis Inc says ongoing and future trials using oral formulation of SCY-078 are unaffected by this regulatory action . Scynexis -meeting with FDA to discuss these data and to agree on subsequent clinical studies with iv formulation of SCY-078 is scheduled for Q2 of 2017 .Scynexis -FDA has informed company to hold initiation of any new clinical studies with intravenous (IV) formulation of SCY-078 until FDA completes review.  Full Article

Scynexis enters into loan and security agreement with Solar Capital
Wednesday, 5 Oct 2016 04:03pm EDT 

Scynexis Inc : On September 30, 2016, Co entered into loan and security agreement with Solar Capital Ltd. - SEC filing .Solar providing Co with 48-month secured term loan of $15 million and all principal and accrued interest on term loan due on Sept 30, 2020.  Full Article

Scynexis announces sale of Cyclophilin inhibitor assets to Cypralis Ltd
Wednesday, 13 Jul 2016 08:30am EDT 

Scynexis Inc : Scynexis announces sale of Cyclophilin inhibitor assets to Cypralis Ltd .Financial terms of agreement were not disclosed..  Full Article

Scynexis says CEO Marco Taglietti purchased 100,000 shares - SEC filing
Tuesday, 28 Jun 2016 10:00am EDT 

Scynexis Inc : CEO Marco Taglietti reports purchase of 100,000 shares of co's common stock on June 24 at $2.39 per share - SEC filing Source: (http://1.usa.gov/29bI1Ch ) Further company coverage: [SCYX.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Scynexis director Guy Macdonald reports purchase of 40,000 shares - SEC filing
Tuesday, 28 Jun 2016 09:59am EDT 

Scynexis Inc : Director Guy Macdonald reports purchase of 40,000 shares of co's common stock on June 24 at $2.39 per share - SEC filing Source: (http://1.usa.gov/290khhU ) Further company coverage: [SCYX.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Scynexis receives orphan drug designation for SCY-078
Friday, 13 May 2016 08:00am EDT 

Scynexis Inc : Scynexis Inc Receives orphan drug designation for SCY-078 for the treatment of invasive Candida infections .Expects top line data from two ongoing phase 2 studies of SCY-078's oral formulation in June and July 2016.  Full Article

Scynexis reports Q1 loss of $0.52 per share
Monday, 9 May 2016 09:25am EDT 

Scynexis Inc : Qtrly revenue $64,000 versus $65,000 . Q1 earnings per share view $-0.63, revenue view $100000.00 -- Thomson Reuters I/B/E/S . Scynexis, inc. Reports first quarter 2016 financial results and provides company update . Q1 loss per share $0.52 .Q1 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.  Full Article

Scynexis Inc receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078
Thursday, 28 Jan 2016 09:05am EST 

Scynexis Inc:Announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track and Qualified Infectious Disease Product (QIDP) designations for the intravenous (IV) formulation of SCY-078.SCYNEXIS' novel antifungal product, for the indications of invasive candidiasis (including candidemia) and invasive aspergillosis.  Full Article

SCYNEXIS Inc appoints Eric Francois as Chief Financial Officer
Monday, 2 Nov 2015 05:26pm EST 

SCYNEXIS Inc:Announced the appointment of Eric Francois as Chief Financial Officer, effective immediately.  Full Article

SCYNEXIS Inc appoints Marco Taglietti as president - Form 8-K
Tuesday, 29 Sep 2015 05:20pm EDT 

SCYNEXIS Inc:Says that on Sept. 24, the board appointed Marco Taglietti as president of SCYNEXIS effective immediately.Says Taglietti will continue in his existing roles as chief executive officer and as a member of the board of SCYNEXIS.  Full Article

More From Around the Web

BRIEF-Scynexis says to present SCY-078 data on lead anti-infective candidate

* Scynexis inc says to present scy-078 data on novel lead anti-infective candidate